Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHV-1100 + natural killer cells
- Development stage
- Unknown
- Lead developer
- Biohaven
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BHV-1100 is a bispecific small molecule Antibody Recruiting Molecule (ARM) developed by Biohaven Pharmaceuticals in strategic alliance with PeptiDream for the treatment of multiple myeloma. It is designed to target the CD38 protein, which is highly overexpressed on multiple myeloma cells. The mechanism of action involves BHV-1100 binding to CD38 on tumor cells and simultaneously to human immunoglobulin (Ig), which recruits and activates natural killer (NK) cells—specifically autologous cytokine-induced memory-like (CIML) NK cells—to induce antibody-dependent cell cytotoxicity (ADCC). This approach is intended to destroy cancer cells while avoiding the NK cell fratricide often associated with other CD38-targeted therapies. The therapy is administered as a combination of BHV-1100, autologous CIML NK cells, and immunoglobulin, and has received FDA Orphan Drug designation for multiple myeloma.
- Other names
- CD38-ARMCD-38-ARMCD 38-ARMBHV-1100 + CIML NK cells
02
Targets
CD38 (Cluster of Differentiation 38)IgG Fc (Immunoglobulin G Fc region)
Beyond the preview
Go deeper on BHV-1100 + natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHV-1100 + natural killer cells.